|Awarded On||November 19, 2014|
|Title||Inhibitors of Hydrogen Sulfide Biosynthesis: Preclinical Development of Novel Colorectal Cancer Therapies|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Mark Hellmich|
Texas ranks third among all the states for the highest incidence and expected deaths due to colorectal cancer. For advanced disease, chemotherapy with or without a drug called Cetuximab (which blocks epidermal growth factor receptor signaling) helps the patient live longer. However, up to 50% of patients with colorectal cancer have mutations in genes called KRAS or BRAF that make their tumor resistant to the drug Cetuximab. Currently, doctors do not recommend using the drugs like Cetuximab if the patient’s tumor has one of these genetic mutations. Therefore, treatment options are limited for almost half of all patients with advanced colorectal cancer. We have recently discovered that an enzy...